Searched for: person:papadj01
Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line
Shaw, Aubie; Papadopoulos, John; Johnson, Curtis; Bushman, Wade
BACKGROUND: Stromal-epithelial signaling plays an important role in prostate development and cancer progression. Study of these interactions will be facilitated by the use of suitable prostate cell lines in appropriate model systems. METHODS: We have isolated an immortalized prostate mesenchymal cell line from the mouse E16 urogenital sinus (UGS). We characterized its expression of stromal differentiation markers, response to androgen stimulation, ability to induce and participate in prostate morphogenesis, response to Shh stimulation, and interaction with prostate epithelial cells. RESULTS: UGSM-2 cells express vimentin and smooth muscle actin, but not the mature smooth muscle markers myosin and desmin. This expression profile is consistent with a myofibroblast phenotype. Unlike other fibroblasts such as 3T3, UGSM-2 cells express androgen receptor mRNA and androgen stimulation increases proliferation. UGSM-2 cells are viable when grafted with embryonic UGS under the renal capsule and participate in glandular morphogenesis, but are not capable of inducing prostate morphogenesis of isolated UGS epithelium. Co-culture of UGSM-2 cells with human BPH-1 cells or co-grafting in vivo results in organized clusters of BPH-1 cells surrounded by a mantle of UGSM-2 cells. UGSM-2 cells are responsive to Sonic hedgehog (Shh), an important signaling factor in prostate development, and mimic the transcriptional response of the intact UGS mesenchyme. In co-cultures with BPH-1, UGSM-2 cells exhibit a robust transcriptional response to Shh secreted by BPH-1. CONCLUSIONS: UGSM-2 is a urogenital sinus mesenchyme cell line that can be used to study stromal-epithelial interactions that are important in prostate biology
PMCID:2802279
PMID: 16752376
ISSN: 0270-4137
CID: 83985
Treatment of moderate to severe rheumatoid arthritis with IL1-Trap [Meeting Abstract]
Bingham, CO; Genovese, M; Moreland, L; Papadopoulos, J; Parsey, MV
ISI:000224551500281
ISSN: 0003-4967
CID: 49057
The critical care pharmacist: an essential intensive care practitioner
Papadopoulos, John; Rebuck, Jill A; Lober, Cheryl; Pass, Steven E; Seidl, Edward C; Shah, Rina A; Sherman, Deb S
Clinical pharmacy services in the critical care setting have expanded dramatically and include assisting physicians in pharmacotherapy decision making, providing pharmacokinetic consultations, monitoring patients for drug efficacy and safety, providing drug information, and offering medical education to physicians, nurses, and patients. Measurable clinical effects of these services include reduced drug errors and adverse drug events, decreased morbidity and mortality rates, and a positive pharmacoeconomic impact by decreasing overall health care costs
PMID: 12432975
ISSN: 0277-0008
CID: 83982
Utilization of a glucagon infusion in the management of a massive nifedipine overdose [Case Report]
Papadopoulos, J; O'Neil, M G
This case report describes a continuous i.v. infusion of glucagon used to reverse the cardiovascular manifestations of a nifedipine overdose in a patient who presented after a massive nifedipine extended-release tablet ingestion. In this patient, glucagon appeared to be effective in the management of this toxicologic emergency.
PMID: 10802424
ISSN: 0736-4679
CID: 635322
Hematogenous candidiasis in critically ill adult patients: Epidemiology, risk factors and management
Papadopoulos, J
Hematogenous candidiasis is a life-threatening infection that occurs in critically ill patients. The incidence has increased dramatically over the past decade and Candida species are currently the fourth most common organism recovered from blood cultures in hospitalized patients. Numerous risk factors have been identified that predispose a patient to the development of hematogenous candidiasis. Diagnosis is often difficult in the clinical setting. Pharmacologic options for the management of hematogenous candidiasis includes amphotericin B, fluconazole, and flucytosine. Evidence from clinical trials indicate that fluconazole is as effective and better tolerated than amphotericin B for the management of hematogenous candidiasis in critically ill patients
SCOPUS:0032466031
ISSN: 0897-1900
CID: 638042